Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.38 |
| ▸ | ALB | P02768 | 1/20 | 0.37 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.37 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.37 |
| ▸ | CD40 | P25942 | 1/20 | 0.35 |
| ▸ | EPOR | P19235 | 1/20 | 0.35 |
| ▸ | RRM1 | P23921 | 1/20 | 0.33 |
| ▸ | CCKAR | P32238 | 1/20 | 0.33 |
| ▸ | CCKBR | P32239 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.32 |
| ▸ | FNTB | P49356 | 1/20 | 0.32 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12743650 | 1.00 | GLP1R (0.48) | GLP1RDPP7ALBNOD1GNAI3 | |
| SCHEMBL8107176 | 0.93 | GLP1R (0.48) | GLP1RALBEPORCCKARCCKBR | |
| SCHEMBL8116035 | 0.89 | GLP1R (0.50) | GLP1RDPP7ALBNOD1GNAI3 | |
| SCHEMBL14500432 | 0.87 | GLP1R (0.56) | GLP1RCCKARCCKBR | |
| SCHEMBL8115335 | 0.87 | GLP1R (0.56) | GLP1RCCKARCCKBR | |
| SCHEMBL14500495 | 0.86 | ALB (0.43) | GLP1RALBNOD1EPOR | |
| SCHEMBL14500437 | 0.86 | GLP1R (0.48) | GLP1RALBCCKARCCKBR | |
| SCHEMBL14500436 | 0.86 | GLP1R (0.48) | GLP1RALBCCKARCCKBR | |
| SCHEMBL12147636 | 0.85 | GLP1R (0.47) | GLP1RDPP7NOD1GNAI3GNAO1 | |
| SCHEMBL14500475 | 0.84 | GLP1R (0.53) | GLP1RALBCCKARCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150374843-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INTERNATIONAL B.V. (NL) | 2015-12-31 | — | — | US | disclosed |
| US-20110070165-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO SUISSE SA (CH) | 2011-03-24 | — | — | US | disclosed |
| US-7910088-B2 | Multivalent constructs for therapeutic and diagnostic applications | BRACCO SUISSE SA (CH) | 2011-03-22 | — | — | US | disclosed |
| US-7211240-B2 | Multivalent constructs for therapeutic and diagnostic applications | BRACCO INTERNATIONAL B.V. (NL) | 2007-05-01 | — | — | US | disclosed |
| US-20040210041-A1 | Multimeric proteins for use in the treatment and detection of cell proliferative disorders | ARBOGAST CHRISTOPHE (FR) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110070165-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | CD47, BCR, CD44 | GLP1R 2595/4885DPP7 1750/4885ALB 589/4885 |
| US-20150374843-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | CD47, BCR, CD44 | GLP1R 2595/4885DPP7 1750/4885ALB 589/4885 |
| US-20040210041-A1 | Multimeric proteins for use in the treatment and detection of cell proliferative disorders | MKI67, TP53, VHL | GLP1R 4619/4885DPP7 3202/4885ALB 1656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.